Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Return on Equity (2016 - 2025)

Lipocine's Return on Equity history spans 13 years, with the latest figure at 0.35% for Q3 2025.

  • For Q3 2025, Return on Equity fell 15.0% year-over-year to 0.35%; the TTM value through Sep 2025 reached 0.35%, down 15.0%, while the annual FY2024 figure was 0.0%, 58.0% up from the prior year.
  • Return on Equity reached 0.35% in Q3 2025 per LPCN's latest filing, down from 0.25% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.11% in Q3 2022 to a low of 0.76% in Q4 2023.
  • Average Return on Equity over 5 years is 0.3%, with a median of 0.33% recorded in 2023.
  • Peak YoY movement for Return on Equity: surged 178bps in 2021, then tumbled -74bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.02% in 2021, then crashed by -1714bps to 0.29% in 2022, then plummeted by -160bps to 0.76% in 2023, then surged by 100bps to 0.0% in 2024, then crashed by -84197bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Return on Equity are 0.35% (Q3 2025), 0.25% (Q2 2025), and 0.27% (Q1 2025).